Acomo: Cocoa-nuts. Cofinimmo: Strong operational start of the year. IMCD: Favourable start of the year. Randstad: Capital Markets Event 2025; rewriting the industry. Signify: Calm 1Q25 before tariff storm. Universal Music Group: EU to probe planned acquisition of Downtown Music. 1Q25 preview. WDP: Good investment, lighter LFL, guidance reconfirmed. Xior Student Housing: Strong organic trends continue. Events Calendar
Inventiva announced publication in the peer-reviewed medical journal Clinical Gastroenterology and Hepatology, of its analysis on new non-invasive biomarker signatures predictive of histology response following treatment with lanifibranor (pan-PPAR agonist) in patients with MASH and fibrosis. While there are multiple diagnostic scores currently available, we are encouraged to learn that Inventiva's test suggested better predictive accuracy than existing options including FIB4. With recruitment i...
Xior reported EPRA EPS of 0.43 that slightly beat our 0.42 expectation (excl. IFRIC costs). Xior NRI was flat yoy after its disposal program of FY24, but like-for-like growth remained high at 5.5%. LTV% also fell below 50% at 48.8%. Xior repeated its flat EPRA EPS outlook for FY25 of 2.21 per share. Xior expects an underlying strong FY25 thanks to a mix of factors: new assets + lfl growth of >5% and cost savings. The cost of debt decreased slightly from 3.10% (FY24) to 3.04%. The asset disposal ...
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor ► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological endpoints, suggested better predictive accuracy than other diagnostic scores available including FIB4, FIBC3, ABC3D, NFS, ELF and MACK-3 ► ...
Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor ► Des signatures de biomarqueurs ont été développées pour prédire la réponse histologique au traitement par lanifibranor chez les patients atteints de MASH avec fibrose ► Les signatures de biomarqueurs développées pour l’amélioration de la fibrose, la résolution de la MASH et les critères histologiques composites, ont suggéré une meilleure prédictivité que les ...
proposition is to freeze the indexation for social rents for 2025 and 2026. The government plans to eliminate the rent increase for social housing in 2025 and 2026, setting the maximum rent increase to 0%. A compensation scheme is outlined to address the loss of rental income due to the rent freeze, with EUR 270m reserved in 2026 and 405m in both 2027 and 2028. The compensation applies to the entire social housing segment to avoid conflicts with European State Aid rules. As Xior NL is about 50% ...
In 2H24, Barco was already showing signs of recovery following two challenging years. Also in 1Q25 Barco experienced a solid quarter with y/y growth in each of its divisions. We updated our model after the 1H25 trading update as Barco indicated that US tariffs are causing disruptions in global markets and supply chains, leading to reduced visibility and increased uncertainty. Barco is actively taking steps to protect its margins and market shares. However, Barco also highlighted that the impact ...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 22, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total am...
Ackermans & van Haaren: Another Delen Private Bank acquisition in the Netherlands. Ahold Delhaize: Peer Albertsons FY24/25 results. ASML: 1Q25 results; already weaker ahead of the tariffs. Barco: Calm before the storm. Heineken: In the hold. Melexis: Partial move to China. Staffing sector: Hays' 3Q24/25 trading update; in line. Vopak: New industrial terminal or energy transition facility? WDP: €60m investment with KDL
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.